Evidence map›Paper›PMID 23397535›Full record

ArticleSeminars in liver disease2012

Prevention and treatment of intestinal failure-associated liver disease in children.

Bram P Raphael, Christopher Duggan

Open access · greenAbstract read
In one paragraph

Article in Seminars in liver disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Monitoring of long-term parenteral nutrition in children with intestinal failure.JGH open : an open access journal of gastroenterology and hepatology · 2019
    Review
  9. Intestinal failure: a review.F1000Research · 2018
    Review
  10. Article
  11. Article
  12. New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bram P RaphaelDivision of Gastroenterology and Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Christopher Duggan
Boston Children's Hospital · US

Funding

ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
Patient-oriented Research in Pediatric Diarrheal DiseasesK24HD058795 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI DUGGAN, CHRISTOPHER P · 2010 to 2014
$956k
NICHD NIH HHS K24 HD058795NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

Intestinal failure-associated liver disease (IFALD), a serious complication occurring in infants, children, and adults exposed to long-term parenteral nutrition (PN), causes a wide-spectrum of disease, ranging from cholestasis and steatosis to fibrosis and eventually cirrhosis. Known host risk factors for IFALD include low birth weight, prematurity, short bowel syndrome, and recurrent sepsis. The literature suggests that components of PN may also play a part of the multifactorial pathophysiology. Because some intravenous lipid emulsions (ILEs) may contribute to inflammation and interfere with bile excretion, treatment with ILE minimization and/or ILEs composed primarily of omega-3 fatty acids can be helpful, but requires careful monitoring for growth failure and essential fatty acid deficiency (EFAD). Data from randomized controlled trials are awaited to support widespread use of these approaches. Other IFALD treatments include cycling PN, ursodeoxycholic acid, sepsis prevention, photoprotection, and polyvinylchloride-free tubing. Management and prevention of IFALD remains a clinical challenge.

Indexed as

Cholagogues and CholereticsCholestasisFat Emulsions, IntravenousFatty LiverHumansIntestinal DiseasesLiver CirrhosisLiver DiseasesParenteral NutritionUrsodeoxycholic AcidCholagogues and CholereticsFat Emulsions, IntravenousUrsodeoxycholic Acid

Identifiers

PMID23397535
PMCPMC4878432
OpenAlexW1971134736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.